Saikosaponin-d (SSd), a SERCA inhibitor, suppresses excess ER Ca2+ reuptake and cell proliferation in ADPKD cells by inducing autophagy through the CaMKKβ-AMPK-mTOR signaling pathway, which indicates that SSd might be a potential treatment for ADPKD and that SERCA might be a novel target for ADPKD therapy [117]. The gene discussed is CAMKK2; the disease is autosomal dominant polycystic kidney disease.